TGFBR1 and chronic kidney disease: Our study showed that FXR activation inhibited the TGFBR1/TAK1 pathway, which was activated in CKD rats and HASMCs cultured in osteogenic medium, causing a reduction in the expression of pro-inflammatory cytokines and postponing the formation of vascular calcification.